Houston Timbery
|Subscribers
About
Dbol Tren Test Cycle
An Overview of Anabolic Steroids (Anabolic–androgenic steroids)
Published for educational purposes – no endorsement or instruction is given regarding their use for sports, bodybuilding, or other non‑medical purposes.
---
1. What Are Anabolic Steroids?
Definition: Synthetic derivatives of the male sex hormone testosterone that promote muscle growth (anabolism) and can also increase secondary sexual characteristics (androgenic effects).
Classification: They belong to a family called steroids—organic compounds with four interconnected rings, derived from cholesterol.
1.1 Chemical Structure
Feature Description
Core skeleton Four fused carbon rings (three six‑membered, one five‑membered).
Functional groups Hydroxyl (-OH), ketone (=O), and other substituents at specific positions.
Steroid nomenclature Uses systematic names based on ring numbering (A–D) and functional group locations.
1.2 Biosynthesis Pathway
Cholesterol → Pregnenolone
Pregnenolone → Progesterone
Progesterone → Testosterone → Estradiol
2. Key Pharmacological Properties
Property Relevance to Therapeutic Use
Potency Determines minimal effective dose; high potency reduces risk of off‑target effects.
Selectivity High receptor subtype selectivity limits side effects such as vasoconstriction or hormonal imbalance.
Metabolic Stability Influences duration of action and dosing frequency.
Toxicity Profile Acute toxicity, organ-specific damage (hepatic, renal).
Drug–Drug Interactions CYP450 inhibition/induction can alter plasma levels of concomitant medications.
---
4. Experimental Design for Comparative Evaluation
A. In‑Vitro Potency & Selectivity Assays
Radioligand Binding
- Use membranes from cells expressing α2A, α2B, and α2C receptors.
- Determine IC50 values for each compound against each receptor subtype.
Functional G‑Protein Activation
- Measure inhibition of cAMP production in HEK293 cells stably expressing human α2A.
- Calculate EC50 and maximal efficacy (% of control).
Cross‑Receptor Profiling
- Test activity at off‑target receptors (e.g., 5‑HT2A, β‑adrenergic) to assess selectivity.
Expected Outcomes
Compound α₂A IC₅₀ (µM) EC₅₀ (nM) Max. Efficacy (%)
4‑(p‑MeO‑Ph) – Cl ~0.02 5 95
4‑(p‑MeO‑Ph) – F ~0.05 15 90
A lower IC₅₀/EC₅₀ indicates higher affinity, while efficacy close to 100 % confirms full agonism.
---
Conclusion
SAR Findings
- The 4‑p‑methoxyphenyl substituent is crucial for activity; it provides the necessary lipophilic and electronic environment that interacts with the receptor pocket.
- Fluorine improves potency compared to chlorine due to optimal size, electronegativity, and polarizability, whereas bromine’s larger size reduces binding affinity.
Optimal Substituent
- 4‑p‑methoxy‑fluoro (compound 3) is the most potent analog, showing the lowest IC₅₀/EC₁₀ values.
Future Directions
- Further optimization could involve varying the halogen position or introducing additional electron-withdrawing/donating groups at other ring positions to fine-tune receptor interaction and pharmacokinetics.
- Structural biology studies (e.g., crystallography, cryo-EM) of the receptor in complex with compound 3 would clarify binding mode and guide rational design.
---
Prepared by:
Your Name
Lead Medicinal Chemist
---
End of Memorandum
